Caladrius Biosciences, Inc. (CLBS): Product News News

CLBS – Reports results from the predetermined interim analysis in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial of 110 patients to evaluate the safety and efficacy of the Company’s CLBS03 as a treatment for recent-onset type 1 diabetes.


Key Facts Surrounding This News Item


  • CLBS had a POWR Rating of B (Buy) coming into today.
  • CLBS was 18.68% above its 10-Day Moving Average coming into today.
  • CLBS was 30.91% above its 20-Day Moving Average coming into today.
  • CLBS was 38.78% above its 50-Day Moving Average coming into today.
  • CLBS was 54.29% above its 100-Day Moving Average coming into today.
  • CLBS was 45.35% above its 200-Day Moving Average coming into today.
  • CLBS had returned +63.25% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Caladrius Biosciences, Inc. (CLBS)


Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. View our full CLBS ticker page with ratings, news, and more.

CLBS at a Glance

CLBS Current POWR Rating™
Overall POWR Rating™
CLBS Current Price $4.74 0.84%
More CLBS Ratings, Data, and News

CLBS Price Reaction

The day of this event (Mar. 8, 2018)
CLBS Closing Price$5.37 6.28%
CLBS Volume165,800
156.83% from avg
Leading up to this event
CLBS 1-mo return42.89%
After this event
CLBS 1-day return3.24%
CLBS 3-day return0.35%
CLBS 5-day return0.87%

CLBS Price Chart


The Top Stocks For 2019

More Caladrius Biosciences, Inc. (CLBS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLBS News
Page generated in 0.8088 seconds.